

Case Report

Dual Pathology Breast Carcinoma: A Report of Two Cases

Mohd Saufee Al Firdaus Mohd Ismail¹, Norlia Abdullah¹ (✉), Suria Hayati Md Pauzi², Tan Geok Chin², Fuad Ismail³

¹Department of Surgery, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, 56000 Cheras, Kuala Lumpur, Malaysia

²Department of Pathology, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, 56000 Cheras, Kuala Lumpur, Malaysia

³Department of Oncology, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, 56000 Cheras, Kuala Lumpur, Malaysia

Abstract

Dual pathology breast carcinoma, whether unifocal, multifocal or multicentric may significantly impact patient prognosis. Certain histological combinations are associated with favourable outcomes, while others may indicate a more aggressive disease. We presented a report of two women with different pathological combinations. The first case had multicentric cancers of the left breast. She underwent neoadjuvant chemotherapy, then nipple-sparing mastectomy with axillary dissection and immediate transverse rectus abdominis myocutaneous (TRAM) breast reconstruction. Histopathological assessment revealed a combination of metaplastic carcinoma and invasive micropapillary carcinoma; both aggressive subtypes. Post adjuvant radiotherapy, she remained disease-free for five years. The second case had a unifocal right breast cancer managed with breast-conserving surgery and sentinel lymph node biopsy. Histopathology revealed a combination of invasive carcinoma of no special type (NST) and invasive papillary carcinoma. These subtypes are associated with a more favourable prognosis. Post radiotherapy and on endocrine therapy, this patient remains well at 2 years follow-up. These cases demonstrate the prognostic variability in dual histopathology breast cancers and highlights the importance of individualised treatment. Both patients remain disease free despite having dual pathology breast carcinoma which seem to suggest a more aggressive disease behaviour.

Keywords: Breast cancer; carcinoma; dual pathology; metaplastic; multicentric, micropapillary; multifocal; papillary

Correspondence:

Norlia Abdullah. Department of Surgery, Hospital Canselor Tuanku Muhriz, Hospital Canselor Tuanku Muhriz, Universiti Kebangsaan Malaysia, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Cheras, Kuala Lumpur, Malaysia. Tel: +603-91455795/6201 E-mail: norlia@hctm.ukm.edu.my, norliapermata@gmail.com

Date of submission: 20 Apr, 2025

Date of acceptance: 17 Jul, 2025

Introduction

Dual pathological malignant subtypes within the same breast may significantly influence one's prognosis. This is because certain histological combinations are associated with either favourable or poor clinical outcomes (1). Breast cancer may present as a unifocal or multifocal disease, whereby multiple tumours are located in the same quadrant. Multicentric disease refers to tumours located in different quadrants of the same breast. Contemporary classification often group

multifocal and multicentric presentations under the collective term multifocal multicentric breast carcinoma (MMBC), recognising their shared clinical features and implications.

MMBC has been identified as an independent factor associated with more aggressive disease behaviour, including increased recurrence risk and reduced disease-free survival (DFS) and overall survival (OS), when compared to unifocal breast cancer (2,3).

These two cases reported breast cancer cases involving two distinct histopathological subtypes, occurring in both MMBC and unifocal disease. Our aim was to contribute to the limited literature on these rare presentations and their clinical outcome.

Case report

Case 1

A 40 year-old Para 4 presented with a lump in her left breast for 3 months duration. Clinical examination revealed a 6.5 x 7.5 cm mass involving the upper two quadrants of the left breast with a palpable axillary lymph node. Bedside ultrasound found this mass to be irregular with a left axillary lymph node that had loss of fatty hilum (size 1.04 cm x 1.26 cm). The contralateral breast and axilla were normal. Her mammogram image showed a BIRADS 4B lesion. The core biopsy confirmed an invasive ductal carcinoma of no special type; oestrogen receptor (ER) and progesterone receptor (PR) were both negative while HER2 receptor was positive (3+). Computer tomography (CT) staging of the thorax, abdomen and pelvis (TAP) was clear of any distant metastasis. She was staged as cT3N1aM0, indicative of locally advanced breast cancer (Stage IIIA). The patient

received six cycles of neoadjuvant chemotherapy; initially with 5-fluorouracil, epirubicin and cyclophosphamide (FEC) for 3 cycles followed by docetaxel from the fourth to sixth cycle. The tumour showed a good response and the patient subsequently underwent a left nipple-sparing mastectomy, axillary dissection and reconstruction with a unipedicled ipsilateral transverse rectus abdominis myocutaneous (TRAM) flap surgery. Post-mastectomy histopathology revealed two distinct cancer types in the different quadrants of the same breast. The upper outer quadrant (UOQ) lesion that measured 21 mm was a Bloom and Richardson grade 3 had features of metaplastic breast carcinoma (Fig. 1). However, the upper inner quadrant (UIQ) lesion which measured 6 mm was a Bloom and Richardson grade 2 invasive micropapillary carcinoma (Fig. 2). All lymph nodes were negative for malignancy (0/8).

The patient subsequently completed 15 fractions of adjuvant radiotherapy (40 Gy) and was planned for targeted therapy (trastuzumab). However, she missed the opportunity to undergo this treatment. After 5 years follow-up in our centre, the patient remained disease free but requested for a transfer of care to another centre due to logistical reasons.




FIGURE 1: Histopathology of Case 1; the UOQ lesion; (A) The larger tumour was composed of sheets and clusters of neoplastic cells without tubule formation (H&E, 10x); (B) The tumour cells were polygonal in shape, with pleomorphic vesicular nuclei and abundant eosinophilic cytoplasm. No obvious intracellular keratinization or intercellular bridge were observed (H&E, 20x); (C) The tumour cells showed positive expression for squamous marker, p63 (IHC, 20x); (D) The tumour cells showed positive expression for CK5/6 (IHC, 20x)




FIGURE 2: Histopathology of Case 1; the UIQ lesion; (A) A separate tumour nodule in the upper inner quadrant of breast (H&E x 10); (B) The tumour forms aggregated with papillary-like patterns devoid of central fibrovascular cores (H&E X 20); (C) Oestrogen receptor was negative (IHC x 20); (D) HER2 protein expression was positive (IHC x 20)

Case 2

A 67 year-old woman presented with a painless right breast lump. She had no other local or constitutional symptoms. Thirty years ago, she had received hormonal therapy to treat recurrent miscarriages. The treatment consisted of dydrogesterone and later, medroxyprogesterone, for a total of 3 years but she failed to conceive.

Breast examination revealed a mass in the upper outer quadrant, with no palpable axillary lymph nodes. Bedside ultrasound of the lump was 1.2 x 1.8 x 1.3 cm. An ultrasound guided core needle biopsy of the lesion confirmed it to be an invasive breast carcinoma, Bloom and Richardson grade 2, ER-positive (strong, >95%), PR-negative and HER2-negative. Staging scans (ultrasonography of abdomen and chest radiograph) showed no distant metastases. The patient underwent surgery; a right breast wide local excision and sentinel lymph node biopsy (SLNB). Histopathology revealed two different cancer pathologies within the same lesion, which consisted of 70% invasive papillary carcinoma and 30% invasive carcinoma of no special type (Fig. 3). All lymph nodes were negative for malignancy (0/8 lymph nodes; 6 sentinel lymph nodes with 2 para sentinel lymph nodes). The final staging was pT1N0M0.

Postoperatively, the patient was started on endocrine therapy (T. Tamoxifen 20 mg once daily) and completed 40 Gy of adjuvant radiotherapy in 15 fractions to the right breast. Upon follow-up for the past two years, the patient remained well, with no signs of recurrence.

Discussion

MMBC may present as either a single or mixed histopathological subtype, each carrying distinct prognostic implications. Previous studies by Budzik et al. (2021) and Guan et al. (2020) have demonstrated that single breast cancer pathology, especially pure mucinous carcinoma is associated with a more favourable prognosis compared to mixed variants (1,2). Among the latter, combinations such as invasive ductal carcinoma (IDC) with invasive micropapillary carcinoma (IMPC) are linked to poorer outcomes than IDC alone or IDC with ductal carcinoma in situ (DCIS) (3,4). In Case 1, two rare and aggressive histological subtypes; metaplastic breast carcinoma (MBC) and IMPC were identified concurrently within the same breast. MBC and IMPC are individually uncommon, with reported incidences of 0.2-2% and 3-6%, respectively (5,6). To our knowledge, this represents the first documented case of MMBC with MBC and IMPC within the same breast, and current




FIGURE 3: Histopathology of Case 2; (A) The smaller part of the tumour was composed of invasive carcinoma of no special type (H&E x 20); (B) The larger part of the tumour is composed of invasive papillary carcinoma (H&E x 10); (C) The papillary component demonstrated neoplastic cells arranged in papillary architecture with central fibrovascular core (arrowed) (H&E x 40); (D) The neoplastic cells were negative for P63 immunohistochemistry (arrowed) (H&E x 20)

literature offers no prognostic data on this unique combination.

Both MBC and IMPC are aggressive, with high recurrence and metastatic rates (7,8). Despite this, the patient remained disease-free at five years post-treatment, likely due to effective neoadjuvant chemotherapy, surgery and radiotherapy, despite not having had targeted therapy. Chemotherapy resulted in complete resolution of nodal involvement and clear surgical margins; factors known to significantly improve DFS and OS. This outcome is consistent with existing data reporting five-year survival rates of 71% for MBC and 87.5% for IMPC (8,9).

Interestingly, the IDC in the case above was initially identified on core biopsy but was absent in the final surgical specimen. This discrepancy may be explained by several factors: chemotherapy-induced histological transformation, the biopsy that removed 6 cores may have removed the small area involved or a differential response to chemotherapy where the IDC component was eradicated while MBC and IMPC persisted (10).

Surgical excision with clear margins remains the cornerstone of MMBC management. While both mastectomy and breast-conserving surgery are

acceptable, achieving negative margins is critical in reducing recurrence risk and improving long-term outcomes (11,12). In Case 1, the patient has had five years of disease free survival, after radiotherapy, despite the absence of targeted therapy.

Malignant papillary neoplasms consist of papillary DCIS, encapsulated papillary carcinoma, solid papillary carcinoma and Invasive Papillary Carcinoma (IPC) is the rarest amongst these, forming 13-20% of papillary neoplasms and 0.5% of invasive breast cancer. IPC, commonly occurs in postmenopausal women and is often associated with invasive breast cancer of a non-specific type or papillary DCIS, as in Case 2. IPC is characterised by positive oestrogen and progesterone receptors with no amplification of the HER2 gene and a low Ki-67 proliferation index. Although IPC has malignant histological features similar to those of IDC, it has a favourable prognosis (13). Patient number 2 remained in remission post-surgery, radiotherapy and on endocrine therapy after follow-up of two years.

To maximise clinical outcome, in cases of mixed lesions, treatment decisions should be based on the type of lesion with the higher/highest degree of malignancy (13).

Conclusion

The prognosis of dual breast cancer histopathology is influenced by various factors. Based on our literature review, Case 1 is the first reported case of MMBC with MBC and IMPC within the same breast. Treatment decisions should be based on the type of lesion with the higher/highest degree of malignancy. Given the rarity of dual pathology breast carcinomas, as demonstrated by these two cases, further studies are warranted to explore their biological behaviour and treatment response.

Author Contributions: Initial draft & Data acquisition: MSAMI; Main clinician, Conceptualization & Final editing: NA; Preparation, reporting of pathological slides of Case 1 and editing: SHMP; Preparation & reporting of pathological slides of Case 2 and editing: TGC; Oncological treatment and editing: FI.

Funding: None

Conflict of Interest: The authors declare that there was no conflict of interest.

Ethics Statement: Informed consent was obtained from the patients for publication of this case series.

References

1. Budzik MP, Fudalej MM, Badowska-Kozakiewicz AM. Histopathological analysis of mucinous breast cancer subtypes and comparison with invasive carcinoma of no special type. *Sci Rep* 2021; 11(1): 5770.
2. Guan X, Xu G, Shi A, et al. Comparison of clinicopathological characteristics and prognosis among patients with pure invasive ductal carcinoma, invasive ductal carcinoma coexisted with invasive micropapillary carcinoma, and invasive ductal carcinoma coexisted with ductal carcinoma in situ: A retrospective cohort study. *Medicine* 2020; 99(50): e23487.
3. Lang Z, Wu Y, Li C, Li X, Wang X, Qu G. Multifocal and multicentric breast carcinoma: A significantly more aggressive tumor than unifocal breast cancer. *Anticancer Res* 2017; 37: 4593-8.
4. Tabár L, Dean PB, Tucker FL et al. Multifocal and diffusely infiltrating breast cancers are highly fatal subgroups needing further improvement in diagnostic and therapeutic strategies. *Eur J Radiol* 2023; 164: 110854.
5. Ye F, Yu P, Li N, et al. Prognosis of invasive micropapillary carcinoma compared with invasive ductal carcinoma in breast: A meta-analysis of PSM studies. *Breast* 2020; 51: 11-20.
6. Rajan R, Abdullah N, Abdullah NMA, Mohd Kassim AY. Metaplastic breast carcinoma with upper limb gangrene. *Breast Cancer* 2017; 9: 297-9.
7. Lee JH, Ryu JM, Lee SK et al. Clinical characteristics and prognosis of metaplastic breast cancer compared with invasive ductal carcinoma: A propensity-matched analysis. *Cancers* 2023; 15(5): 1556.
8. Lewis GD, Xing Y, Haque W et al. Prognosis of lymphotropic invasive micropapillary breast carcinoma analyzed by using data from the National Cancer Database. *Cancer Commun* 2019; 39(1): 60.
9. Yang YL, Liu BB, Zhang X, Fu L. Invasive micropapillary carcinoma of the breast: An update. *Arch Pathol Lab Med* 2016; 140(8): 799-805.
10. Abdullah N, Rizuana IH, Goh JHL, Lee QZ, Md Isa N, Md Pauzi, SH. Bilateral metachronous breast malignancies: Malignant phylloides and invasive breast carcinoma - A case report. *Front Oncol* 2023; 13: 1034556.
11. Kuan L, Tiong LU, Parkyn R, Walters D, Lai C, Walsh D. Disease recurrence and survival in patients with multifocal breast cancer: A follow-up study with 7-year results. *ANZ J Surg* 2017; 87(10): E125-8.
12. Zhang Y, Liu F, Gao Q et al. Comparing the outcome between multicentric/multifocal breast cancer and unifocal breast cancer: A systematic review and meta-analysis. *Front Oncol* 2022; 12: 1042789.
13. Wang S, Zhang Q, Mao X. Invasive papillary carcinoma of the breast. *Front Oncol* 2024; 14: 1374091.